ES2174073T3 - Forma farmaceutica solida para uso oral. - Google Patents

Forma farmaceutica solida para uso oral.

Info

Publication number
ES2174073T3
ES2174073T3 ES96918678T ES96918678T ES2174073T3 ES 2174073 T3 ES2174073 T3 ES 2174073T3 ES 96918678 T ES96918678 T ES 96918678T ES 96918678 T ES96918678 T ES 96918678T ES 2174073 T3 ES2174073 T3 ES 2174073T3
Authority
ES
Spain
Prior art keywords
administration
solid pharmaceutical
ingrediently
easily soluble
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96918678T
Other languages
English (en)
Inventor
Ubaldo Conte
Lauretta Maggi
Alberto Reiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
APR Applied Pharma Research SA
Original Assignee
APR Applied Pharma Research SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by APR Applied Pharma Research SA filed Critical APR Applied Pharma Research SA
Application granted granted Critical
Publication of ES2174073T3 publication Critical patent/ES2174073T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

POR COMBINACION DEL MISMO INGREDIENTE ACTIVO EN UNA FORMA FACILMENTE SOLUBLE EN AGUA O EN LIQUIDOS ACUOSOS Y EN UNA FORMA DE LIBERACION DEMORADA Y PROGRAMABLE EN LA MISMA FORMA FARMACEUTICA SOLIDA PARA ADMINISTRACION ORAL, PREFERENTEMENTE EN FORMA DE UNA TABLETA DE DOBLE CAPA, SE OBTIENEN ELEVADOS NIVELES PLASMATICOS INMEDIATAMENTE DESPUES DE LA ADMINISTRACION, CON LO QUE SE CONSIGUE UN RAPIDO EFECTO TERAPEUTICO Y EL MANTENIMIENTO DE ELEVADOS NIVELES PLASMATICOS DURANTE UN PERIODO PROLONGADO DE TIEMPO TRAS LA ADMINISTRACION. LAS DOS FORMAS DE INGREDIENTES ACTIVOS VAN ACOMPAÑADAS POR LOS APROPIADOS ADYUVANTES Y EXCIPIENTES QUE SON CAPACES DE PRODUCIR LA RAPIDA DISGREGACION DE LA CAPA QUE CONTIENE EL INGREDIENTE ACTIVO EN UNA FORMA FACILMENTE SOLUBLE Y LA LIBERACION DEMORADA DEL INGREDIENTE ACTIVO EN LA FORMA DE LIBERACION DEMORADA.
ES96918678T 1995-06-09 1996-06-05 Forma farmaceutica solida para uso oral. Expired - Lifetime ES2174073T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95MI001223A IT1276689B1 (it) 1995-06-09 1995-06-09 Forma farmaceutica solida ad uso orale

Publications (1)

Publication Number Publication Date
ES2174073T3 true ES2174073T3 (es) 2002-11-01

Family

ID=11371782

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96918678T Expired - Lifetime ES2174073T3 (es) 1995-06-09 1996-06-05 Forma farmaceutica solida para uso oral.

Country Status (9)

Country Link
EP (1) EP0833618B1 (es)
KR (1) KR19990021897A (es)
AT (1) ATE215816T1 (es)
CA (1) CA2224267A1 (es)
DE (1) DE69620606T2 (es)
ES (1) ES2174073T3 (es)
IT (1) IT1276689B1 (es)
PT (1) PT833618E (es)
WO (1) WO1996041617A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
US6638948B1 (en) * 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
DE19816070A1 (de) 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
IT1313590B1 (it) * 1999-08-03 2002-09-09 Formenti Farmaceutici Spa Composizioni a rilascio controllato di acido acetilsalicilico.
DE19954421A1 (de) 1999-11-12 2001-05-31 Lohmann Therapie Syst Lts Filmförmige Zubereitung zur biphasigen Freisetzung pharmakologisch wirksamer oder anderer Substanzen
KR100446829B1 (ko) * 2002-02-20 2004-09-04 한국유나이티드제약 주식회사 가용화된 피록시캄을 함유한 확산형 정제의 조성물 및그의 제조방법
AU2013267036B2 (en) * 2003-03-21 2016-05-26 Mcneil-Ppc, Inc. Non-steroidal anti-inflammatory drug dosing regimen
US20040186180A1 (en) 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
CN1758904A (zh) 2003-03-21 2006-04-12 麦克内尔-Ppc股份有限公司 非甾体抗炎药物的给药方案
GB0501809D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Anti-migraine formulations
WO2006080498A1 (ja) * 2005-01-31 2006-08-03 Kyowa Hakko Kogyo Co., Ltd. オルニチン塩酸塩を含有する錠剤
CN101410123A (zh) 2006-03-28 2009-04-15 杰佛林制药公司 低剂量的双氯芬酸和β－环糊精的制剂
WO2009021127A2 (en) * 2007-08-07 2009-02-12 Neurogen Corporation Controlled released compositions
CA2696063C (en) * 2007-08-15 2014-05-06 Mcneil-Ppc, Inc. Immediate release and sustained release ibuprofen dosing form
JP5520235B2 (ja) 2008-02-08 2014-06-11 コルゲート・パーモリブ・カンパニー 塩の製造のための方法
BRPI0906452A2 (pt) * 2008-02-08 2015-07-14 Colgate Palmolive Co Composição, dispositivo, método para produzir ou inibir a formação de cáries dentais, reduzir, reparar ou inibir as leões pré-cárie do esmalte, reduzir ou inibir a desmineralização e promover a remineralização dos dentes, reduzir a hipersensibilidade dos dentes, reduzir ou inibir a gengivite, promover a cura de feridas ou de cortes na boca, reduzir os níveis de bactérias que produzem ácido, aumentar os níveis relativos de bactérias arginolíticas, inibir a formação de composição, dispositivo, método para reduzir ou inibir a formação de cáries dentais, reduzir, reparar ou inibir as leões pré-cárie dp esmalte, reduzir ou inibir a desmineralização e promover a remineralização dos dentes, reduzir a hipersibilidade dos dentes, reduzir ou inibir a gengivite, promover a cura de feridas ou de cortes na boca, reduzir os níveis de bactérias que produzem ácido, aumentar os níveis relativos de bactérias arginolíticas, inibir a formação de biofilme microbiano na cavidade oral, elevar e/ou manter o ph da placa em níveis de pelos menos um ph de 5,5, reduzir o acúmulo de placa, tratar, aliviar ou reduzir a boca seca, limpar os dentes e a cavidade oral, reduzir a erosão, branquear os dentes, imunizar os dentes contra as bactérias cariogênicas, e/ ou promover a saúde sistêmica, incluindo a saúde cardiovascular, e, uso de um aminoácido básico
EP2255797A4 (en) * 2008-02-22 2011-09-07 Hanall Biopharma Co Ltd COMPOSITE PREPARATION
BR112012014739A2 (pt) 2009-12-18 2016-04-05 Colgate Palmolive Co métodos para a produção de solução de bicarbonato de arginina de alta concentração em alta pressão
MX2012005971A (es) 2009-12-18 2012-06-13 Colgate Palmolive Co Metodos para la produccion a baja presion de bicarbonato de arginina.
KR101320802B1 (ko) * 2010-02-16 2013-10-23 주식회사 드림파마 방출 제어형 사포그릴레이트 염산염 함유 다층 정제
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
AU2012230733B2 (en) 2011-03-23 2016-10-20 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
KR102124459B1 (ko) 2018-05-02 2020-06-23 주식회사 에코앤휴먼 종패 부착용 식생부 및 이를 포함하는 인공어초
CN110037994B (zh) * 2019-05-24 2022-04-12 中国药科大学 一种布洛芬速释缓释双层片及其制备方法
CN114983973B (zh) * 2022-05-31 2023-05-05 石家庄四药有限公司 一种乌拉地尔缓释胶囊及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
FI93924C (fi) * 1991-09-17 1995-06-26 Martti Lauri Antero Marvola Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata

Also Published As

Publication number Publication date
DE69620606D1 (de) 2002-05-16
PT833618E (pt) 2002-09-30
ATE215816T1 (de) 2002-04-15
DE69620606T2 (de) 2002-10-24
WO1996041617A1 (en) 1996-12-27
EP0833618B1 (en) 2002-04-10
ITMI951223A0 (it) 1995-06-09
CA2224267A1 (en) 1996-12-27
EP0833618A1 (en) 1998-04-08
KR19990021897A (ko) 1999-03-25
IT1276689B1 (it) 1997-11-03
ITMI951223A1 (it) 1996-12-09

Similar Documents

Publication Publication Date Title
ES2174073T3 (es) Forma farmaceutica solida para uso oral.
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
ES2187822T3 (es) Comprimidos de disgregacion rapida.
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
ES2117015T3 (es) Composiciones que contienen sumatriptan.
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
AR021535A1 (es) Formas de dosificacion de liberacion controlada que comprenden zolpidem o sales del mismo
ES2185816T3 (es) Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico.
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
UY25544A1 (es) Forma de dosificación de nefazodona
ECSP034869A (es) Una composicion para la piel, permeable selectiva inhibidora de ciclooxigenasa-2
ES2106818T3 (es) Composicion multicapa que contiene antagonistas de histamina o secotina.
ES488168A0 (es) Proceso para la preparacion de tabletas farmaceuticas o medicinales de administracion oral, con liberacion retardada delagente activo, en tabletas en las que la cantidad de libera-cion del agente activo es predeterminada.
CR6326A (es) Formulaciones farmaceuticas de liberacion controlada
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
DE602004032149D1 (de) Oros-push-stick für die kontrollierte abgabe von wirkstoffen
AR034517A1 (es) Formulacion farmaceutica
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
AR046146A1 (es) Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso
AR087240A2 (es) Composiciones farmaceuticas que tienen epinastina y pseudoefedrina
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
AR043412A1 (es) Formulaciones farmaceuticas que comprenden un agente enmascarante del sabor amargo
ES2185310T3 (es) Agente antivirico herbario.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 833618

Country of ref document: ES